Single Ascending Dose, First-in-Human Study on Safety, Tolerability and Pharmacokinetics of BAY1161116

Summary

This study will be conducted in a single center, double-blind with 6 dose escalation groups to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses of BAY1161116.

Timeline

Start

2017-04-27

Primary completion

2017-09-08

Completion

2018-01-31

Outcome

Outcome not reported

Stopped: “Study early terminated due to lower drug exposure”

Drugs

Indications